Last reviewed · How we verify
Olodaterol-Tiotropium
Olodaterol-Tiotropium is a fixed-dose combination of a long-acting beta-2 agonist (olodaterol) and a long-acting muscarinic antagonist (tiotropium) that work synergistically to relax airway smooth muscle and improve airflow.
Olodaterol-Tiotropium is a fixed-dose combination of a long-acting beta-2 agonist (olodaterol) and a long-acting muscarinic antagonist (tiotropium) that work together to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Olodaterol-Tiotropium |
|---|---|
| Sponsor | Fraunhofer-Institute of Toxicology and Experimental Medicine |
| Drug class | Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) |
| Target | Beta-2 adrenergic receptor; M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Olodaterol activates beta-2 adrenergic receptors to increase cAMP and cause bronchodilation, while tiotropium blocks M3 muscarinic receptors to prevent acetylcholine-induced bronchoconstriction. Together, these complementary mechanisms provide sustained bronchodilation and improved lung function in obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- ANTES B+ Clinical Trial (PHASE4)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
- Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
- Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
- Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
- Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: